On July 1, 2025, ArriVent BioPharma, Inc. entered into an underwriting agreement for a public offering of 2,482,692 shares of common stock priced at $19.50 per share, expected to raise around $75 million before expenses, with an additional option for underwriters to purchase up to 576,923 more shares. The offering is set to close on July 3, 2025.